An 8-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Cariprazine in the Treatment of Pediatric Subjects (5 to 17 Years of Age) With Autism Spectrum Disorder
Latest Information Update: 28 Oct 2024
At a glance
- Drugs Cariprazine (Primary) ; Cariprazine (Primary)
- Indications Pervasive child development disorders
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 24 Oct 2024 Status changed from active, no longer recruiting to completed.
- 21 Aug 2024 Planned End Date changed from 25 Nov 2025 to 1 Oct 2024.
- 21 Aug 2024 Planned primary completion date changed from 26 Oct 2024 to 3 Sep 2024.